Estimating the market for tuberculosis drugs in industrialized and developing nations

International Journal of Tuberculosis and Lung Disease

Volumn 12, Issue 10, 2008, Pages 1173-1181

  Schwalbe, N R ^a,c   Wells, W A ^a   Geaneotes, A P ^b,d   Forcellina, A ^b,e   Lee, M G ^b   DiCola, L ^b   Ignatius, H R ^a   Walker, C L ^b   Raafat, T ^b   Patel, N ^b  

^a GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

^b IQVIA   (United States)

^c GAVI Alliance   (Switzerland)

^d HARVARD UNIVERSITY   (United States)

^e MCKINSEY AND COMPANY   (United States)

Author keywords

Global estimate; Market size; Tuberculosis drugs

Indexed keywords

TUBERCULOSTATIC AGENT;

ARTICLE; DATA BASE; DEVELOPING COUNTRY; DRUG COST; DRUG MANUFACTURE; DRUG MARKETING; GEOGRAPHIC DISTRIBUTION; GOVERNMENT; HUMAN; INDUSTRIALIZATION; MEDICAL AUDIT; MEDICAL STAFF; PRIORITY JOURNAL; RELIABILITY; SHORT COURSE THERAPY; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DRUG INDUSTRY; DRUG UTILIZATION; HUMANS; MARKETING OF HEALTH SERVICES; TUBERCULOSIS, PULMONARY;

EID: 53549101948     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Arrow K, Panosian C, Gelband H, Committee on the Economics of Antimalarial Drugs, eds. Saving lives, buying time: economics of malaria drugs in an age of resistance. Washington DC, USA: Institute of Medicine/National Academies Press, 2004.
2. Norval P Y, Blomberg B, Kitler M E, Dye C, Spinaci S. Estimate of the global market for rifampicin-containing fixed-dose combination tablets. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S292-S300; discussion S17-S21.
3. International AIDS Vaccine Initiative. Forecasting demand for preventive HIV vaccines in India. New York, NY, USA: IAVI, 2007.
4. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2007. WHO/HTM/ TB/2007.376. Geneva, Switzerland: WHO, 2007.
5. Wilkinson D, Floyd K, Gilks C F. Costs and cost-effectiveness of alternative tuberculosis management strategies in South Africa - implications for policy. S Afr Med J 1997; 87: 451-455.
6. Floyd K, Wilkinson D, Gilks C. Comparison of cost-effectiveness of directly observed treatment (DOT) and conventionally delivered treatment for tuberculosis: experience from rural South Africa. BMJ 1997; 315: 1407-1411.
7. Brown R E, Miller B, Taylor W R, et al. Health care expenditures for tuberculosis in the United States. Arch Intern Med 1995; 155: 1595-1600.
8. Taylor Z, Marks S M, Rios Burrows N M, Weis S E, Stricof R L, Miller B. Causes and costs of hospitalization of tuberculosis patients in the United States. Int J Tuberc Lung Dis 2000; 4: 931-939.
9. Palmer C S, Miller B, Halpern M T, Geiter L J. A model of the cost-effectiveness of directly observed therapy for treatment of tuberculosis. J Public Health Manag Pract 1998; 4: 1-13.
10. Stop TB Partnership/World Health Organization. Global plan to stop TB, 2006-2015. Annex 1: methods used to estimate costs, funding and funding gaps. WHO/HTM/STB/2006.38. Geneva, Switzerland: WHO, 2006.
11. Floyd K, Skeva J, Nyirenda T, Gausi F, Salaniponi F. Cost and cost-effectiveness of increased community and primary care facility involvement in tuberculosis care in Lilongwe District, Malawi. Int J Tuberc Lung Dis 2003; 7 (Suppl 1): S29-S37.
12. Kemp J R, Mann G, Simwaka B N, Salaniponi F M, Squire S B. Can Malawi's poor afford free tuberculosis services? Patient and household costs associated with a tuberculosis diagnosis in Lilongwe. Bull World Health Organ 2007; 85: 580-585.
13. Vassall A, Compernolle P. Estimating the resource needs of scaling-up HIV/AIDS and tuberculosis interventions in sub-Saharan Africa: a systematic review for national policy makers and planners. Health Policy (Amsterdam, Netherlands) 2006; 79: 1-15.
14. Mohan C I, Bishai D, Cavakante S, Chaisson R E. The cost-effectiveness of DOTS in urban Brazil. Int J Tuberc Lung Dis 2007; 11:27-32.
15. Resch S C, Salomon J A, Murray M, Weinstein M C. Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med 2006; 3: e241.
16. Global Alliance for TB Drug Development. The economics of TB drug development. New York, NY, USA: Global Alliance for TB Drug Development, 2001.
17. World Health Organization. Global TB drug facility: prospectus. Annex D: WHO survey on TB drug supply experiences in WHO member states. WHO/CDS/STB/2001.10a. Geneva, Switzerland: WHO, 2001.
18. Global Alliance for TB Drug Development. Pathway to patients: charting the dynamics of the global TB drug market. New York, NY, USA: Global Alliance for TB Drug Development, 2007.
19. Global Alliance for TB Drug Development. Pathway to patients: country reports. New York, NY, USA: Global Alliance for TB Drug Development, 2007. http://www.tballiance.org/aaa/groundwork.php Accessed November 2007.
20. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO/HTM/TB/2006.362. Geneva, Switzerland: WHO, 2006.
21. World Health Organization. Global health atlas. Geneva, Switzerland: WHO, 2005. www.who.int/globalatlas/dataQuery/default.asp Accessed July 2008.
22. World Bank. Country groups. Washington DC, USA: World Bank, 2007. http://web.worldbank.org/WBSITE/EXTERNAL/DATASTATISTICS/0contentMDK: 20421402∼pagePK:64133150∼piPK:64133175∼theSitePK:239419,00.html Accessed November 2007.
23. World Health Organization. Anti-tuberculosis drug resistance in the world. Report no. 4. WHO/HTM/TB/2008.394. Geneva, Switzerland: WHO, 2008.
24. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2008. WHO/HTM/ TB/2008.393. Geneva, Switzerland: WHO, 2008.
25. Corbett E L, Watt C J, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003; 163: 1009-1021.
26. Prasad R, Nautiyal R G, Mukherji P K, Jain A, Singh K, Ahuja R C. Treatment of new pulmonary tuberculosis patients: what do allopathic doctors do in India? Int J Tuberc Lung Dis 2002; 6: 895-902.
27. Rajeswari R, Balasubramanian R, Bose M S, Sekar L, Rahman F. Private pharmacies in tuberculosis control - a neglected link. Int J Tuberc Lung Dis 2002; 6: 171-173.
28. Olle-Goig J E, Cullity J E, Vargas R. A survey of prescribing patterns for tuberculosis treatment amongst doctors in a Bolivian city. Int J Tuberc Lung Dis 1999; 3: 74-78.
29. Sumartojo E M, Geiter L J, Miller B, Hale B E. Can physicians treat tuberculosis? Report on a national survey of physician practices. Am J Public Health 1997; 87: 2008-2011.
30. Center for Global Development. Consultation report of the Global Health Forecasting Working Group. Washington DC, USA: Center for Global Development, 2007.